RECRUITINGPhase 4INTERVENTIONAL
Artificial Intelligence to Measure Adherence to Oral Medication
Early-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication
About This Trial
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis.
Who May Be Eligible (Plain English)
Who May Qualify:
- Enrolled in a CSC program
- Prescribed an oral antipsychotic
Who Should NOT Join This Trial:
- none
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Enrolled in a CSC program
* Prescribed an oral antipsychotic
Exclusion Criteria:
* none
Treatments Being Tested
OTHER
Smartphone App
artificial intelligence (AI) smartphone app to provide support for medication adherence
OTHER
Usual Care
Usual Care provided by CSC clinic
Locations (5)
Citrus Health
Hialeah, Florida, United States
InterAct
Grand Rapids, Michigan, United States
InterAct of Michigan
Kalamazoo, Michigan, United States
Red Rock
Oklahoma City, Oklahoma, United States
Family and Children's Services
Tulsa, Oklahoma, United States